CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from first use more than a third have stopped ...

When it comes to weight loss, providers and patients argue that GLP-1 medications are not a one-for-one swap and that volatile insurance coverage contradicts the science and experience of people ...

Study finds many GLP-1 weight-loss patients discontinue treatment too soon. GLP-1 drugs such as Wegovy, Ozempic, and Zepbound are a class of medications primarily taken to treat Type 2 diabetes ...

They dropped the weight, so they’re dropping their weight-loss drug. Most people taking GLP-1 drugs like Ozempic and Wegovy do not stay on their prescribed treatment for a minimum of 12 weeks ...

Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications.It ...

Gastrointestinal issues are common in patients taking GLP-1 weight loss drugs like Ozempic and Wegovy, but there are some lesser known side effects that range from bothersome to bizarre.

When it comes to weight loss, providers and patients argue that GLP-1 medications are not a one-for-one swap and that volatile insurance coverage contradicts the science and experience of people ...